undamentalytics Newsletter
Sign in

Xeris Biopharma Holdings, Inc. key statistics and ratios

In fiscal 2025, Xeris Biopharma Holdings, Inc. had an operating margin of 8.5%, debt equal to 1706.3% of equity and a current ratio of 2.19. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Operating margin−408.8%−232.2%−74.3%−26.8%−16.6%8.5%10.9%
Net margin−446.0%−247.5%−85.9%−38.0%−27.0%0.2%−5.1%
Free-cash-flow margin−396.1%−194.8%−93.3%−28.7%−18.2%9.8%—
Return on equity—−190.3%−134.8%————
Return on assets−57.3%−53.0%−29.2%−18.7%−17.0%0.2%−4.3%
Asset turnover0.130.210.340.490.630.830.84
Current ratio5.401.802.541.641.672.191.45
Debt to equity257.8%92.5%436.4%——>999%—
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/m0.9x1.3x
Effective tax rate—————0.0%—
R&D as % of revenue102.4%50.7%19.0%13.6%12.6%10.7%10.4%
SG&A as % of revenue360.8%253.5%124.9%89.1%80.5%62.5%62.1%
Capital spending as % of revenue1.8%2.2%0.0%0.0%0.0%0.0%—
Free cash flow ÷ net income—————>999%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 5 checks passed · June 30, 2026
What it owns · $412m
Short-term assets $275mLonger-term assets $137m
What it owes, and who funded it · $422m
Short-term liabilities $190mLonger-term liabilities $232mShareholders' equity $-10m
  • Short-term assets cover short-term liabilities $275m of assets due within a year against $190m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $275m short-term assets against $232m of longer-dated liabilities.
  • More cash than debt $122m of cash against $253m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $57m of operating cash flow against $253m of debt.
  • Operating profit covers interest at least five times over Operating income of $37m against $28m of interest.

From Xeris Biopharma Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

15 /100

Weak moat

How hard Xeris Biopharma Holdings's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -18.0% of total assets over 5 years.

  • Durability 10 / 20

    Operating margin has been a median -33.8%; its worst year was -223.2%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 5 years, at a median -21.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (20 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: EOLS vs XERSIRWD vs XERSHROW vs XERSINVA vs XERS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xeris Biopharma Holdings, Inc.